Tiziana Enters a Collaboration Agreement with FHI Clinical to Conduct a Phase 2 Clinical Trial for Treating Hospitalized Severe COVID-19 Patients with Intranasal Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody NEW

Tiziana Enters a Collaboration Agreement with

FHI Clinical to Conduct a Phase 2 Clinical Trial for Treating Hospitalized Severe COVID-19 Patients with Intranasal Foralumab, a Fully

Human Anti-CD3 Monoclonal Antibody

NEW YORK & LONDON, June 23, 2021 - Tiziana

Life Sciences plc (NASDAQ: TLSA, LSE: TILS), ("Tiziana" or the "Company"),

a biotechnology company focused on innovative therapeutics for oncology, neurology, inflammation and infectious diseases, announces

that it has signed an agreement with FHI Clinical, a global clinical contract research

organization (CRO), to conduct a Phase 2 Proof-of-concept study in Brazil to evaluate the safety, tolerability and efficacy

of intranasal Foralumab in hospitalized patients with severe coronavirus disease 2019 (COVID-19)

and pulmonary inflammation.

subsidiary of FHI 360, FHI Clinical specializes in the clinical development

of drugs for infectious diseases (https://www.fhiclinical.com).

The company's involvement with COVID-19 includes Phase 1 to Phase 3 clinical trials for vaccines and therapeutics, as well as observational

studies to collect data about the characteristics and course of infection. With experience conducting related studies across 16 countries

and 43 states in the United States, FHI Clinical has a large network of clinical sites throughout the world to expedite COVID-19 trials.

In this clinical trial, Foralumab will be delivered

intranasally through a metered-dose nasal atomization device. Nasal administration of Foralumab

is a highly innovative approach to treat patients with autoimmune diseases where the immune system may be dysregulated. Several studies

have suggested that there is dysregulation in the immune system of patients with COVID-19.

placebo-controlled, double-blind, proof-of-concept study is designed to expand on the preliminary findings of safety, tolerability

and efficacy of intranasal administration of Foralumab observed in mild to moderate non-hospitalized COVID-19 patients (https://ir.tizianalifesciences.com/news-releases/news-release-details/tiziana-life-sci-plc-positive-data-nasal-administration).

Thus, this study will examine attenuation of pulmonary pathology in hospitalized patients with severe COVID-19. Up to seven sites in Brazil

will be engaged to conduct this study. Eighty hospitalized patients with severe COVID-19 and evidence of pulmonary involvement on a computed

tomography (CT) scan at screening will be enrolled. Patients will be randomized 1:1 to receive intranasal Foralumab 100 g. Additionally,

the study will also evaluate the effect of Foralumab on resolution of symptoms by chest CT, inflammatory biomarkers, T-cell subpopulations,

safety and mucosal inflammatory response following 14 days of intranasal administration.

experience is uniquely suited to the needs of this Phase 2 study as we are able to pull from past outbreak experience, including rapid

study start-up in research-na ve areas to leveraging existing global research networks and contributing to local health systems,"

said Ted FitzGerald, FHI Clinical President and CEO.

"We excel at addressing the complex aspects of infectious disease trials that require thorough planning and contingency planning."

pleased to move forward with FHI Clinical on our next COVID-19 trial. After a successful proof-of-mechanism trial in mild to moderate

COVID-19 outpatients with intranasal Foralumab earlier this year, the next step is to test it in more severe hospitalized patients with

pulmonary inflammation," said Dr. Neil Graham, Chief Medical Officer at Tiziana Life Sciences.

who arranged for the release of this announcement on behalf of the Company was Dr. Kunwar Shailubhai, Chief Executive Officer and Chief

Scientific Officer of the Company.

Foralumab (formerly NI-0401), the only entirely

human anti-CD3 mAb, shows reduced release of cytokines after IV administration in patients with Crohn's disease with decreases in the

classic side effects of cytokine release syndrome and improves the overall safety profile of Foralumab. In a humanized mouse model (NOD/SCID

IL2 c-/-), it was shown that whilst targeting the T cell receptor, orally administered Foralumab modulates immune responses of the

T cells, enhances regulatory T-cells (Tregs) and thus provides therapeutic benefit in treating inflammatory and autoimmune diseases without

the occurrence of potential adverse events usually associated with parenteral mAb therapy (Ogura M. et al., 2017). Based on animal studies,

the nasal and oral administration of Foralumab offers the potential for the immunotherapy of autoimmune and inflammatory diseases in a

safe manner by the induction of Tregs.

About Tiziana Life Sciences

Life Sciences plc (NASDAQ: TLSA, LSE: TILS) is a UK

biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and

immunology. In addition to Milciclib (a CDK inhibitor being developed in oncology), the Company is also developing Foralumab in

COVID-19, multiple sclerosis, and Crohns Disease. Foralumab is the only second generation fully human anti-CD3 monoclonal antibody

in clinical development in the world. This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory

diseases, such as nonalcoholic steatohepatitis (NASH), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), Crohn's

disease, psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The Company is accelerating

development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammatory

Forward-Looking Statements

Certain statements made in this announcement

are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's

current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as anticipates,'

expects,' intends,' plans,' believes,' 'seeks,' estimates,'

and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance

and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are

difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements.

The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements,

which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement

relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly

any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after

the date of this announcement except as required by law or by any appropriate regulatory authority.

For further enquiries: